|
1
|
Hoh CK, Schiepers C, Seltzer MA, Gambhir
SS, Silverman DH, Czernin J, Maddahi J and Phelps ME: PET in
oncology: Will it replace the other modalities? Semin Nucl Med.
27:94–106. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Brock CS, Meikle SR and Price P: Does
fluorine-18 fluorodeoxyglucose metabolic imaging of tumors benefit
oncology? Eur J Nucl Med. 24:691–705. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Bar-Shalom R, Valdivia AY and Blaufox MD:
PET imaging in oncology. Semin Nucl Med. 30:150–185. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Whiting P, Rutjes AW, Reitsma JB, Bossuyt
PM and Kleijnen J: The development of QUADAS: A tool for the
quality assessment of studies of diagnostic accuracy included in
systematic reviews. BMC Med Res Methodol. 3:252003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Zamora J, Abraira V, Muriel A, Khan K and
Coomarasamy A: Meta-DiSc: A software for meta-analysis of test
accuracy data. BMC Med Res Methodol. 6:312006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tateishi U, Yamaguchi U, Seki K, Terauchi
T, Arai Y and Kim EE: Bone and Soft-Tissue Sarcoma: Preoperative
Staging with Fluorine 18Fluorodeoxyglucose PET/CT and Conventional
Imaging. Radiology. 245:839–847. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Strobel K, Exner UE, Stumpe KD, Hany TF,
Bode B, Mende K, Veit-Haibach P, von Schulthess GK and Hodler J:
The additional value of CT images interpretation in the
differential diagnosis of benign vs. malignant primary bone lesions
with 18F-FDG-PET/CT. Eur J Nucl Med Mol Imaging. 35:2000–2008.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Shin D, Shon OJ, Han DS, Choi JH, Chun KA
and Cho IH: The clinical efficacy of (18)F-FDG-PET/CT in benign and
malignant musculoskeletal tumors. Ann Nucl Med. 22:603–609. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Charest M, Hickeson M, Lisbona R,
Novales-Diaz JA, Derbekyan V and Turcotte RE: FDG PET/CT imaging in
primary osseous and soft tissue sarcomas: A retrospective review of
212 cases. Eur J Nucl Med Mol Imaging. 36:1944–1951. 2008.
View Article : Google Scholar
|
|
10
|
Piperkova E, Mikhaeil M, Mousavi A, Libes
R, Viejo-Rullan F, Lin H, Rosen G and Abdel-Dayem H: Impact of PET
and CT in PET/CT studies for staging and evaluating treatment
response in bone and soft tissue sarcomas. Clin Nucl Med.
34:146–150. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Fuglø HM, Jørgensen SM, Loft A, Hovgaard D
and Petersen MM: The diagnostic and prognostic value of 18F-FDG
PET/CT in the initial assessment of high-grade bone and soft tissue
sarcoma a retrospective study of 89 patients. Eur J Nucl Med Mol
Imaging. 39:1416–1424. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Sharma P, Khangembam BC, Suman KC, Singh
H, Rastogi S, Khan SA, Bakhshi S, Thulkar S, Bal C, Malhotra A and
Kumar R: Diagnostic accuracy of 18F-FDG PET/CT for detecting
recurrence in patients with primary skeletal Ewing sarcoma. Eur J
Nucl Med Mol Imaging. 40:1036–1043. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Xu R, Kido S, Suga K, Hirano Y, Tachibana
R, Muramatsu K, Chagawa K and Tanaka S: Texture analysis on
(18)F-FDG PET/CT images to differentiate malignant and benign bone
and soft-tissue lesions. Ann Nucl Med. 28:926–935. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Byun BH, Kong CB, Lim I, Kim BI, Choi CW,
Song WS, Cho WH, Jeon DG, Koh JS, Lee SY and Lim SM: Comparison of
(18)F-FDG PET/CT and (99 m) Tc-MDP bone metastasis in osteosarcoma.
Skeletal Radiol. 42:1673–1681. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Iagaru A, Masamed R, Chawla S, Menendez
LR, Fedenko A and Conti PS: F-18 FDG PET and PET/CT Evaluation of
Response to Chemotherapy in Bone and Soft Tissue Sarcomas. Clin
Nucl Med. 33:8–13. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Evilevitch V, Weber WA, Tap WD,
Allen-Auerbach M, Chow K, Nelson SD, Eilber FR, Eckardt JJ,
Elashoff RM, Phelps ME, et al: Reduction of glucose metabolic
activity is more accurate than change in size at predicting
histopathologic response to neoadjuvant therapy in high-grade
soft-tissue sarcomas. Clin Cancer Res. 14:715–720. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Hamada K, Tomita Y, Inoue A, Fujimoto T,
Hashimoto N, Myoui A, Yoshikawa H and Hatazawa J: Evaluation of
chemotherapy response in osteosarcoma with FDG-PET. Ann Nucl Med.
23:89–95. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Benz MR, Czernin J, Allen-Auerbach MS, Tap
WD, Dry SM, Elashoff D, Chow K, Evilevitch V, Eckardt JJ, Phelps
ME, et al: FDG-PET/CT imaging predicts histopathologic treatment
responses after the initial cycle of neoadjuvant chemotherapy in
high-grade soft-tissue sarcomas. Clin Cancer Res. 15:2856–2863.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Im HJ, Kim TS, Park SY, Min HS, Kim JH,
Kang HG, Park SE, Kwon MM, Yoon JH, Park HJ, et al: Prediction of
tumour necrosis fractions using metabolic and volumetric 18F-FDG
PET/CT indices, after one course and at the completion of
neoadjuvant chemotherapy, in children and young adults with
osteosarcoma. Eur J Nucl Med Mol Imaging. 39:39–49. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Byun BH, Kong CB, Lim I, Choi CW, Song WS,
Cho WH, Jeon DG, Koh JS, Lee SY and Lim SM: Combination of 18F-FDG
PET/CT and diffusion-weighted MR imaging as a predictor of
histologic response to neoadjuvant chemotherapy: Preliminary
results in osteosarcoma. J Nucl Med. 54:1053–1059. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Byun BH, Kim SH, Lim SM, Lim I, Kong CB,
Song WS, Cho WH, Jeon DG, Lee SY, Koh JS and Chung SK: Prediction
of response to neoadjuvant chemotherapy in osteosarcoma using
dual-phase (18)F-FDG PET/CT. Eur radiol. 25:2015–2024. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nishio J, Ideta S, Iwasaki H and Naito M:
Scapular osteochondrolipoma: Imaging features with pathological
correlation. Oncol Lett. 6:817–820. 2013.PubMed/NCBI
|
|
23
|
Brenner W, Bohuslavizki KH and Eary JF:
PET Imaging of Osteosarcoma. J Nucl Med. 44:930–942.
2003.PubMed/NCBI
|
|
24
|
Fletcher JW, Djulbegovic B, Soares HP,
Siegel BA, Lowe VJ, Lyman GH, Coleman RE, Wahl R, Paschold JC,
Avril N, et al: Recommendations on the use of 18F-FDG PET in
oncology. J Nucl Med. 49:480–508. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Erdi YE: The use of PET for radiotherapy.
Curr Med Imaging Rev. 3:3–16. 2007. View Article : Google Scholar
|
|
26
|
de G eus-Oei LF, van der Heijden HF,
Corstens FH and Oyen WJ: Predictive and prognostic value of FDG-PET
in nonsmall-cell lung cancer: A systematic review. Cancer.
110:1654–1664. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hillner BE, Siegel BA, Shields AF, Liu D,
Gareen IF, Hunt E and Coleman RE: Relationship between cancer type
and impact of PET and PET/CT on intended management: Findings of
the National Oncologic PET Registry. J Nucl Med. 49:1928–1935.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Boellaard R, O'Doherty MJ, Weber WA,
Mottaghy FM, Lonsdale MN, Stroobants SG, Oyen WJ, Kotzerke J,
Hoekstra OS, Pruim J, et al: FDG PET and PET/CT: EANM procedure
guidelines for tumour PET imaging: Version 1.0. Eur J Nucl Med Mol
Imaging. 37:181–200. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Muheremu A and Niu X: Positron emission
tomography/computed tomography for bone tumors. Oncol Lett.
9:522–526. 2015.PubMed/NCBI
|
|
30
|
Glasser DB, Lane JM, Huvos AG, Marcove RC
and Rosen G: Survival, prognosis and therapeutic response in
osteogenic sarcoma: The Memorial Hospital experience. Cancer.
69:698–708. 1992. View Article : Google Scholar : PubMed/NCBI
|
